Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Aug 2020
Price :
$35
*
At a glance
- Drugs Rucosopasem manganese (Primary)
- Indications Stomatitis
- Focus Adverse reactions
- Sponsors Galera Therapeutics
- 12 Aug 2020 Status changed from recruiting to completed.
- 17 Sep 2019 Planned number of patients changed from 40 to 60.
- 17 Sep 2019 Planned End Date changed from 1 Aug 2019 to 1 Jun 2020.